Copper(I) targeting in the Alzheimer's disease context: a first example using the biocompatible PTA ligand.

Abstract

Copper(I) coordinating ligands in the Alzheimer's disease context have remained unexplored, despite the biological relevance of this redox state of the copper ion. Here, we show that the PTA ligand can remove copper from Aβ, prevent reactive oxygen species production and oligomer formation, two deleterious events in the disease's etiology.

• Authors: E Atrián-Blasco, E Cerrada, A Conte-Daban, D Testemale, P Faller, M Laguna, C Hureau
• Journal: Metallomics : integrated biometal science (Metallomics) Vol. 7 Issue 8 Pg. 1229-32 (Aug 2015) ISSN: 1756-591X [Electronic] England
• PMID: 25926057 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 1,3,5-triaza-7-phosphaadamantane
• Amyloid beta-Peptides
• Organophosphorus Compounds
• Reactive Oxygen Species
• Copper
• Adamantane

Topics

• Adamantane (analogs & derivatives, pharmacology)
• Alzheimer Disease (drug therapy, metabolism)
• Amyloid beta-Peptides (chemistry, metabolism)
• Copper (isolation & purification, metabolism)
• Humans
• Organophosphorus Compounds (pharmacology)
• Oxidation-Reduction
• Reactive Oxygen Species (metabolism)